DOES TESTING FOR SAA IS MORE BENEFICIAL THAN CRP FOR THE FOLLOW-UP OF FMF PATIENTS WITH M694V HETEROZYGOUS OR M694V HOMOZYGOUS MUTATIONS?


Oztas M., Ugurlu S., Selvi O., Ergezen B., Ozdogan H.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 Haziran 2020, cilt.79, ss.843 identifier